The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

MAGEA1  -  melanoma antigen family A, 1

Homo sapiens

Synonyms: Antigen MZ2-E, CT1.1, Cancer/testis antigen 1.1, MAGE-1 antigen, MAGE1, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of MAGEA1

  • These distinctive epigenetic phenotypes of MAGEA1 and MAGEA3 also were observed in pure seminomas and in the seminomatous elements of mixed-type TGCTs [1].
  • However, the MAGEA1 gene that was inactivated and hypermethylated in non-astrocytoma tissues, was partially demethylated in 24.5% of the astrocytoma tissues (co-existence of the hypermethylated and demethylated alleles) [2].
  • It is expressed in a larger proportion of melanoma samples than MAGE-1 [3].
  • Sixteen of 100 primary tumors vs. 69 (48%) of 145 metastases from individual patients expressed MAGE-1 [4].
  • Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder [5].

Psychiatry related information on MAGEA1

  • The sample was derived from the Kungsholmen Project in Stockholm, Sweden, and consisted of (n = 85) healthy older adults (M age = 81.80 years; M MMSE = 28.34) and (n = 21) diagnosed Alzheimer's Disease (AD) patients (Mage = 81.80 years; M MMSE = 23.55) [6].
  • Participants included 39 individuals (Mage = 25.86; 69% female) with a primary diagnosis of panic disorder (with and without agoraphobia) recruited through the general community [7].
  • A downward extension of a Dutch version of Harter's Self-Perception Profile for Children (SPPC) was tested in a Flemish sample of 880 1st to 3rd graders (Mage = 7.18 years, SD = 0.80) [8].

High impact information on MAGEA1

  • A gene family named MAGE codes for antigens recognized by autologous CTL on a melanoma tumor [9].
  • Some of them are encoded by genes MAGE-1 and MAGE-3, which are not expressed in normal tissues except in testis [10].
  • Like the MAGE genes, it is silent in normal tissues with the exception of testis [10].
  • The immunological mechanism, as shown for GM-CSF-transduced DCs, involves MAGE-1-specific CD4(+) and CD8(+) T cells [11].
  • MAGE-type genes are expressed by many tumors of different histological types and not by normal cells, except for male germline cells, which do not express major histocompatibility complex (MHC) molecules [12].

Chemical compound and disease context of MAGEA1


Biological context of MAGEA1


Anatomical context of MAGEA1


Associations of MAGEA1 with chemical compounds

  • Competition experiments using single Ala-substituted peptides indicated that amino acid residues Asp in position 3 and Tyr in position 9 were essential for binding of the MAGE-1 peptide to HLA-A1 [3].
  • Finally, the HLA-B44 photoaffinity labeling, unlike the HLA-A1 and HLA-A29 labeling, was inhibited more efficiently by the corresponding MAGE decapeptides, which is consistent with the reported HLA-B44 peptide-binding motif (glutamic acid in P2, and C-terminal tyrosine or phenylalanine) [18].
  • Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines [24].
  • To estimate the possibility of activating the MAGE-A1 gene with demethylating agents with a view toward clinical use, we assessed the methylation status of its CpG-rich promoter by sodium bisulfite mapping both of samples that express the gene and those that do not [25].
  • Finally, treatment of MAGE-1-mRNA-negative cell lines with 5-Aza-2'-deoxycytidine, a hypomethylating agent known to induce MAGE-1 expression, resulted in the expression of the 72-kDa protein [26].

Physical interactions of MAGEA1


Regulatory relationships of MAGEA1


Other interactions of MAGEA1


Analytical, diagnostic and therapeutic context of MAGEA1

  • The overlapping binding of homologous MAGE peptides by HLA-A1, A29, and B44 is based on different binding principles and may have implications for immunotherapy of MAGE-positive tumors [18].
  • MAGE-1 and MAGE-3 represent targets for specific immunotherapy because they encode peptide antigens which are recognised by cytotoxic T lymphocytes (CTL) when presented by HLA class I molecules, and pilot clinical trials with these peptides are currently in progress [13].
  • We have determined whether esophageal carcinoma patients should be eligible for MAGE-peptide-based vaccine therapies [20].
  • Thus, precisely targeted immunotherapy directed against antigen MZ2-E could be provided to individuals identified by HLA typing and analysis of the RNA of a small tumor sample [34].
  • All three rabbit anti-peptide antisera showed reactivity against the immunizing peptide, and one reacted with the recombinant MAGE-1 protein by immunoblotting, but none reacted with cell lysates from MAGE-1 mRNA-positive cells [35].


  1. Distinctive epigenetic phenotype of cancer testis antigen genes among seminomatous and nonseminomatous testicular germ-cell tumors. Zhang, C., Kawakami, T., Okada, Y., Okamoto, K. Genes Chromosomes Cancer (2005) [Pubmed]
  2. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. Yu, J., Zhang, H., Gu, J., Lin, S., Li, J., Lu, W., Wang, Y., Zhu, J. BMC Cancer (2004) [Pubmed]
  3. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. Gaugler, B., Van den Eynde, B., van der Bruggen, P., Romero, P., Gaforio, J.J., De Plaen, E., Lethé, B., Brasseur, F., Boon, T. J. Exp. Med. (1994) [Pubmed]
  4. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Brasseur, F., Rimoldi, D., Liénard, D., Lethé, B., Carrel, S., Arienti, F., Suter, L., Vanwijck, R., Bourlond, A., Humblet, Y. Int. J. Cancer (1995) [Pubmed]
  5. Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Patard, J.J., Brasseur, F., Gil-Diez, S., Radvanyi, F., Marchand, M., François, P., Abi-Aad, A., Van Cangh, P., Abbou, C.C., Chopin, D. Int. J. Cancer (1995) [Pubmed]
  6. Self-reported memory compensation: similar patterns in Alzheimer's disease and very old adult samples. Dixon, R.A., Hopp, G.A., Cohen, A.L., de Frias, C.M., Bäckman, L. Journal of clinical and experimental neuropsychology : official journal of the International Neuropsychological Society. (2003) [Pubmed]
  7. Perceived health among individuals with panic disorder: associations with affective vulnerability and psychiatric disability. Gregor, K.L., Zvolensky, M.J., Yartz, A.R. J. Nerv. Ment. Dis. (2005) [Pubmed]
  8. Measuring the multidimensional self-concept and global self-worth of 6- to 8-year-olds. Van den Bergh, B.R., de Rycke, L. The Journal of genetic psychology ; child behavior, animal behavior, and comparative psychology. (2003) [Pubmed]
  9. Tumor antigens recognized by T lymphocytes. Boon, T., Cerottini, J.C., Van den Eynde, B., van der Bruggen, P., Van Pel, A. Annu. Rev. Immunol. (1994) [Pubmed]
  10. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Boël, P., Wildmann, C., Sensi, M.L., Brasseur, R., Renauld, J.C., Coulie, P., Boon, T., van der Bruggen, P. Immunity (1995) [Pubmed]
  11. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. Klein, C., Bueler, H., Mulligan, R.C. J. Exp. Med. (2000) [Pubmed]
  12. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. Chaux, P., Vantomme, V., Stroobant, V., Thielemans, K., Corthals, J., Luiten, R., Eggermont, A.M., Boon, T., van der Bruggen, P. J. Exp. Med. (1999) [Pubmed]
  13. Infrequent expression of the MAGE gene family in uveal melanomas. Mulcahy, K.A., Rimoldi, D., Brasseur, F., Rodgers, S., Liénard, D., Marchand, M., Rennie, I.G., Murray, A.K., McIntyre, C.A., Platts, K.E., Leyvraz, S., Boon, T., Rees, R.C. Int. J. Cancer (1996) [Pubmed]
  14. MAGE-1 and MAGE-3 tumor rejection antigens in human germ cell tumors. Cheville, J.C., Roche, P.C. Mod. Pathol. (1999) [Pubmed]
  15. Expression of the TRAG-3 gene in human esophageal cancer: The frequent synchronous expression of MAGE-3 gene. Ohta, M., Tanaka, F., Sadanaga, N., Yamaguchi, H., Inoue, H., Mori, M. Oncol. Rep. (2006) [Pubmed]
  16. Genome-wide Hypomethylation in Human Glioblastomas Associated with Specific Copy Number Alteration, Methylenetetrahydrofolate Reductase Allele Status, and Increased Proliferation. Cadieux, B., Ching, T.T., Vandenberg, S.R., Costello, J.F. Cancer Res. (2006) [Pubmed]
  17. Expression of MAGE genes in human colorectal carcinoma. Mori, M., Inoue, H., Mimori, K., Shibuta, K., Baba, K., Nakashima, H., Haraguchi, M., Tsuji, K., Ueo, H., Barnard, G.F., Akiyoshi, T. Ann. Surg. (1996) [Pubmed]
  18. HLA photoaffinity labeling reveals overlapping binding of homologous melanoma-associated gene peptides by HLA-A1, HLA-A29, and HLA-B44. Luescher, I.F., Romero, P., Kuznetsov, D., Rimoldi, D., Coulie, P., Cerottini, J.C., Jongeneel, C.V. J. Biol. Chem. (1996) [Pubmed]
  19. Cloning and analysis of MAGE-1-related genes. Ding, M., Beck, R.J., Keller, C.J., Fenton, R.G. Biochem. Biophys. Res. Commun. (1994) [Pubmed]
  20. Expression of MAGE genes in esophageal squamous-cell carcinoma. Quillien, V., Raoul, J.L., Heresbach, D., Collet, B., Toujas, L., Brasseur, F. Anticancer Res. (1997) [Pubmed]
  21. The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma. Inoue, H., Mori, M., Honda, M., Li, J., Shibuta, K., Mimori, K., Ueo, H., Akiyoshi, T. Gastroenterology (1995) [Pubmed]
  22. Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family. Tanzarella, S., Russo, V., Lionello, I., Dalerba, P., Rigatti, D., Bordignon, C., Traversari, C. Cancer Res. (1999) [Pubmed]
  23. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Pellat-Deceunynck, C., Mellerin, M.P., Labarrière, N., Jego, G., Moreau-Aubry, A., Harousseau, J.L., Jotereau, F., Bataille, R. Eur. J. Immunol. (2000) [Pubmed]
  24. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Duan, Z., Duan, Y., Lamendola, D.E., Yusuf, R.Z., Naeem, R., Penson, R.T., Seiden, M.V. Clin. Cancer Res. (2003) [Pubmed]
  25. The MAGE-A1 gene expression is not determined solely by methylation status of the promoter region in hematological malignancies. Suyama, T., Ohashi, H., Nagai, H., Hatano, S., Asano, H., Murate, T., Saito, H., Kinoshita, T. Leuk. Res. (2002) [Pubmed]
  26. Monoclonal antibodies against recombinant-MAGE-1 protein identify a cross-reacting 72-kDa antigen which is co-expressed with MAGE-1 protein in melanoma cells. Carrel, S., Schreyer, M., Spagnoli, G., Cerottini, J.C., Rimoldi, D. Int. J. Cancer (1996) [Pubmed]
  27. Metastatic uveal melanoma: an ocular melanoma associated antigen in the serum of patients with metastatic disease. Donoso, L.A., Felberg, N.T., Edelberg, K., Borlinghaus, P., Herlyn, M. Journal of immunoassay. (1986) [Pubmed]
  28. Heterogeneity of melanoma antigen-1 (MAGE-1) gene and protein expression in malignant melanoma. Zuber, M., Spagnoli, G.C., Kocher, T., Lüscher, U., Schaefer, C., Noppen, C., Gudat, F., Harder, F., Heberer, M. European surgical research. Europäische chirurgische Forschung. Recherches chirurgicales européennes. (1997) [Pubmed]
  29. Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells. Mou, D.C., Cai, S.L., Peng, J.R., Wang, Y., Chen, H.S., Pang, X.W., Leng, X.S., Chen, W.F. Br. J. Cancer (2002) [Pubmed]
  30. A novel IFN-gamma regulated human melanoma associated antigen gp33-38 defined by monoclonal antibody Me14/D12. I. Identification and immunochemical characterization. Giuffré, L., Isler, P., Mach, J.P., Carrel, S. J. Immunol. (1988) [Pubmed]
  31. Alternative promoters of gene MAGE4a. De Plaen, E., Naerhuyzen, B., De Smet, C., Szikora, J.P., Boon, T. Genomics (1997) [Pubmed]
  32. Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. Celis, E., Fikes, J., Wentworth, P., Sidney, J., Southwood, S., Maewal, A., Del Guercio, M.F., Sette, A., Livingston, B. Mol. Immunol. (1994) [Pubmed]
  33. Analysis of the tumour suppressor genes, FHIT and WT-1, and the tumour rejection genes, BAGE, GAGE-1/2, HAGE, MAGE-1, and MAGE-3, in benign and malignant neoplasms of the salivary glands. Nagel, H., Laskawi, R., Eiffert, H., Schlott, T. MP, Mol. Pathol. (2003) [Pubmed]
  34. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., Boon, T. Science (1991) [Pubmed]
  35. Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Chen, Y.T., Stockert, E., Chen, Y., Garin-Chesa, P., Rettig, W.J., van der Bruggen, P., Boon, T., Old, L.J. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
WikiGenes - Universities